Exploring Scopoletin's Therapeutic Efficacy in DSS-Induced Ulcerative Colitis: Insights into Inflammatory Pathways, Immune Modulation, and Microbial Dynamics
Inflammation · 26.06.2024 · 48 (2) · 575-589
DOI: 10.1007/s10753-024-02048-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammation, online erschienen am 26.06.2024. Verfasst von Abdelrahim Alqudah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa, Jordan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Gastrointestinal Microbiome, Scopoletin, Anti-Inflammatory Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research was supported by the Deanship of Scientific Research at the Hashemite University, Zarqa, Jordan.
Abstract (Originalsprache)
This study aimed to investigate the therapeutic potential of scopoletin in ulcerative colitis, with a primary focus on its impact on crucial inflammatory pathways and immune responses. A male mouse model of DSS-induced colitis was employed with six distinct groups: a control group, a group subjected to DSS only, three groups treated with varying scopoletin doses, and the final group treated with dexamethasone. The investigation included an assessment of the effects of scopoletin on colitis symptoms, including alterations in body weight, Disease Activity Index (DAI), and histopathological changes in colonic tissue. Furthermore, this study scrutinized the influence of scopoletin on cytokine production, PPARγ and NF-κB expression, NLRP3 inflammasome, and the composition of intestinal bacteria. Scopoletin treatment yielded noteworthy improvements in DSS-induced colitis in mice, as evidenced by reduced weight loss and colonic shortening (p < 0.05, < 0.01, respectively). It effectively diminished TNF-α, IL-1β, and IL-12 cytokine levels (p < 0.01, p < 0.05), attenuated NLRP3 inflammasome activation and the associated cytokine release (p < 0.05, p < 0.01), and modulated the immune response by elevating PPARγ expression while suppressing NF-κB pathway activation (p < 0.05, p < 0.01). Additionally, scopoletin induced alterations in the gut microbiota composition, augmenting beneficial Lactobacillus and Bifidobacteria while reducing E. coli (p < 0.05). It also enhanced tight junction proteins, signifying an improvement in the intestinal barrier integrity (p < 0.05, < 0.01). Scopoletin is a promising therapeutic agent for managing ulcerative colitis, showing benefits that extend beyond mere anti-inflammatory actions to encompass regulatory effects on gut microbiota and restoration of intestinal integrity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa, Jordan.
- Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
- Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan.
- Physiology Department, School of Medicine and Biomedical Sciences, Arabian Gulf University, Manama, Bahrain.
- Department of Physiology and Biochemistry, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
- Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid, 21163, Jordan.
Förderung
- This research was supported by the Deanship of Scientific Research at the Hashemite University, Zarqa, Jordan
Zitieren
APA
Alqudah, A., Qnais, E., Gammoh, O., Bseiso, Y., Wedyan, M., Alqudah, M., Aljabali, A. A. A., & Tambuwala, M. (2024). Exploring Scopoletin's Therapeutic Efficacy in DSS-Induced Ulcerative Colitis: Insights into Inflammatory Pathways, Immune Modulation, and Microbial Dynamics. Inflammation, 48(2), 575-589. https://doi.org/10.1007/s10753-024-02048-9
Vancouver
Alqudah A, Qnais E, Gammoh O, Bseiso Y, Wedyan M, Alqudah M, et al. Exploring Scopoletin's Therapeutic Efficacy in DSS-Induced Ulcerative Colitis: Insights into Inflammatory Pathways, Immune Modulation, and Microbial Dynamics. Inflammation. 2024;48(2):575-589. doi:10.1007/s10753-024-02048-9
BibTeX
@article{Alqudah2024,
author = {Alqudah, Abdelrahim and Qnais, Esam and Gammoh, Omar and Bseiso, Yousra and Wedyan, Mohammed and Alqudah, Mohammad and Aljabali, Alaa A A and Tambuwala, Murtaza},
title = {Exploring Scopoletin's Therapeutic Efficacy in DSS-Induced Ulcerative Colitis: Insights into Inflammatory Pathways, Immune Modulation, and Microbial Dynamics},
journal = {Inflammation},
year = {2024},
volume = {48},
number = {2},
pages = {575--589},
doi = {10.1007/s10753-024-02048-9}
}
EUVIMED